
CorMedix (NASDAQ:CRMD) is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The company is primarily known for its lead product, DefenCath, a novel catheter lock solution designed to prevent catheter-related bloodstream infections (CRBSIs) in patients on hemodialysis through central venous catheters. CorMedix aims to address the significant unmet medical needs in reducing infections in the hospital and dialysis settings, making strides in the fight against antibiotic resistance. With a commitment to innovation and patient care, CorMedix is dedicated to improving outcomes for patients and healthcare systems worldwide.